- Petrol and diesel prices today stable in Hyderabad, Delhi, Chennai and Mumbai on 09 June 2023
- Gold and silver rates today in Delhi, Chennai, Kolkata, Mumbai - 09 June 2023
- Naga Shaurya makes interesting comments on Prabhas
- Congress lambasts Canada over ‘Indira assassination float’
- Kharge, Rahul, Mamata to attend Oppn meet in Patna
- NBK’s ‘Bhagavanth Kesari’ teaser to be screened in 108 theatres on Balayya’s b’day
- Three batches of Haj pilgrims depart from Hyderabad
- Congress to contest in three MLC seats
- Warangal: Minister Errabelli gesture to maid’s daughter’s marriage
- BRS government delaying railway project: BJP
Indian Immunologicals opens serum plant in NZ
Indian Immunologicals Limited (IIL), a leading biologicals company in India, on Monday opened its bovine serum manufacturing facility in New Zealand.
Hyderabad: Indian Immunologicals Limited (IIL), a leading biologicals company in India, on Monday opened its bovine serum manufacturing facility in New Zealand.
Pristine Biologicals (NZ) Limited (PBL), a wholly owned subsidiary of IIL, established the facility which was inaugurated by T Nanda Kumar, Chairman, National Dairy Development Board (NDDB), in the presence of Ms Jo Goodhew, Minister for Food Safety Development & Primary Industries, Government of New Zealand.
In October 2014, IIL established PBL with an objective of gaining control over the supplies of bovine serum, a key ingredient used in vaccine manufacture. Serum from New Zealand is highly regarded as the country is free from several diseases listed by the OIE. The new plant can manufacture up to 300 tonne of serum.
“Pristine would bring the science of biopharmaceuticals to the users of bovine serum and the rigour in quality assurance and management which will in turn ensure that users bring high quality to their products,” stated K V Balasubramaniam, Managing Director, Indian Immunologicals Limited.
The plant will produce key products like new born calf serum, adult bovine serum (NZ origin) and bulk bovine haemoglobin (NZ origin) for biopharmaceutical, research and diagnostic purpose.
The company will collect bovine blood only from EU and USFDA approved abattoirs in closed method under hygienic conditions. All the operations are subjected to daily independent verification by veterinarians employed by Ministry of Primary industries, New Zealand. Special equipment designed to protect the material from microbial contamination will be used in the process.
Adult bovine serum will be processed by trained technicians in a state-of-the-art facility. The serum will be separated from blood, processed, filtered, filled in containers and stored at - 200 C temperature, the company said.